Neuro-Innovators

Neuro-Innovators is pioneering a de-risked, capital-efficient approach to treating neurological disorders by developing combination therapies from existing, brain-penetrant FDA-approved drugs. Its lead asset, NIV-001, targets motor recovery in chronic stroke, a significant unmet need with no current standard of care. The company's strategy is built on a proprietary screening platform and a polypharmacology rationale, aiming to accelerate development timelines and create barriers to entry. Led by a veteran team of neurotech executives and scientists, Neuro-Innovators is positioned to advance its clinical pipeline while expanding its platform to other indications.

Proprietary polypharmacology platform utilizing a 'Mechanisms of Plasticity Matrix' to rationally select and combine existing, FDA-approved drugs to enhance neuroplasticity and neurorestoration for neurological disorders.

The field of neuro-restoration is nascent but growing, with competition from biotechs exploring growth factors, stem cells, and devices. Neuro-Innovators' unique polypharmacy approach using approved drugs differentiates it by offering a potentially faster, lower-cost development path compared to novel biologic or cell therapies.